Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008

Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination... ORIGINAL INVESTIGATION Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008 Luigia Elzi, MD, MSc; Catia Marzolini, PhD; Hansjakob Furrer, MD; Bruno Ledergerber, PhD; Matthias Cavassini, MD; Bernard Hirschel, MD; Pietro Vernazza, MD; Enos Bernasconi, MD; Rainer Weber, MD; Manuel Battegay, MD; for the Swiss HIV Cohort Study Background: Adverse effects of combination antiret- nevirapine (1.95 [1.01-3.81]; P=.050), comedication for roviral therapy (CART) commonly result in treatment an opportunistic infection (2.24 [1.19-4.21]; P=.01), ad- modification and poor adherence. vanced age (1.21 [1.03-1.40] per 10-year increase; P=.02), female sex (1.68 [1.14-2.48]; P=.009), nonwhite ethnic- Methods: We investigated predictors of toxicity- ity (1.71 [1.18-2.47]; P=.005), higher baseline CD4 cell related treatment modification during the first year of count (1.19 [1.10-1.28] per 100/µL increase; P.001), CART in 1318 antiretroviral-naive human immunode- and HIV-RNA of more than 5.0 log copies/mL (1.47 ficiency virus (HIV)–infected individuals from the Swiss [1.10-1.97]; P=.009) were associated with higher rates HIV Cohort Study who began treatment between Janu- of treatment modification. Almost 90% of individuals with ary 1, 2005, and June 30, 2008. treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less Results: The total http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008

Loading next page...
 
/lp/american-medical-association/treatment-modification-in-human-immunodeficiency-virus-infected-S6PuAMgIbF
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2009.432
pmid
20065200
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008 Luigia Elzi, MD, MSc; Catia Marzolini, PhD; Hansjakob Furrer, MD; Bruno Ledergerber, PhD; Matthias Cavassini, MD; Bernard Hirschel, MD; Pietro Vernazza, MD; Enos Bernasconi, MD; Rainer Weber, MD; Manuel Battegay, MD; for the Swiss HIV Cohort Study Background: Adverse effects of combination antiret- nevirapine (1.95 [1.01-3.81]; P=.050), comedication for roviral therapy (CART) commonly result in treatment an opportunistic infection (2.24 [1.19-4.21]; P=.01), ad- modification and poor adherence. vanced age (1.21 [1.03-1.40] per 10-year increase; P=.02), female sex (1.68 [1.14-2.48]; P=.009), nonwhite ethnic- Methods: We investigated predictors of toxicity- ity (1.71 [1.18-2.47]; P=.005), higher baseline CD4 cell related treatment modification during the first year of count (1.19 [1.10-1.28] per 100/µL increase; P.001), CART in 1318 antiretroviral-naive human immunode- and HIV-RNA of more than 5.0 log copies/mL (1.47 ficiency virus (HIV)–infected individuals from the Swiss [1.10-1.97]; P=.009) were associated with higher rates HIV Cohort Study who began treatment between Janu- of treatment modification. Almost 90% of individuals with ary 1, 2005, and June 30, 2008. treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less Results: The total

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jan 11, 2010

References